BioAtla, Inc. (BCAB)

NASDAQ: BCAB · IEX Real-Time Price · USD
+0.06 (1.70%)
Jul 6, 2022 9:36 AM EDT - Market open

Total Valuation

BioAtla has a market cap or net worth of $133.94 million. The enterprise value is -$80.45 million.

Market Cap 133.94M
Enterprise Value -80.45M

Important Dates

The next earnings date is Friday, August 12, 2022, before market open.

Estimated Earnings Date Aug 12, 2022
Ex-Dividend Date n/a

Share Statistics

BioAtla has 37.41 million shares outstanding. The number of shares has increased by 10.97% in one year.

Shares Outstanding 37.41M
Shares Change (YoY) +10.97%
Shares Change (QoQ) +0.90%
Owned by Insiders (%) 16.54%
Owned by Institutions (%) 75.47%
Float 25.74M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 535.77
PB Ratio 0.70
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 13.04, with a Debt / Equity ratio of 0.03.

Current Ratio 13.04
Quick Ratio 12.77
Debt / Equity 0.03
Debt / EBITDA n/a
Debt / FCF n/a

Financial Efficiency

Return on equity (ROE) is -49.90%, which is considered low.

Return on Equity (ROE) -49.90%
Return on Assets (ROA) -41.20%
Return on Capital (ROIC) n/a
Revenue Per Employee $4,464
Profits Per Employee -$1.80M
Employee Count 56
Asset Turnover 0.00
Inventory Turnover n/a


Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

Beta (1Y) n/a
Total Price Change -91.78%
50-Day Moving Average 2.67
200-Day Moving Average 6.69
Average Volume (30 Days) 622,688

Short Selling Information

The latest short interest is 3.96 million, so 10.59% of the outstanding shares have been sold short.

Short Interest 3.96M
Short % of Shares Out 10.59%
Short % of Float 15.40%
Short Ratio (days to cover) 9.82

Income Statement

In the last 12 months, BioAtla had revenue of $250,000 and -100.96 million in losses. Earnings per share was -$2.85.

Revenue 250,000
Gross Profit 250,000
Operating Income -101.99M
Net Income -100.96M
EBITDA -99.62M
EBIT -100.95M
Earnings Per Share (EPS) -$2.85
Full Income Statement

Balance Sheet

The company has $219.43 million in cash and $5.04 million in debt, giving a net cash position of $214.39 million or $5.73 per share.

Cash & Cash Equivalents 219.43M
Total Debt 5.04M
Net Cash 214.39M
Net Cash Per Share $5.73
Book Value 190.05M
Book Value Per Share 5.08
Working Capital 206.83M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$72.36 million and capital expenditures -$433,000, giving a free cash flow of -$72.79 million.

Operating Cash Flow -72.36M
Capital Expenditures -433,000
Free Cash Flow -72.79M
FCF Per Share n/a
Full Cash Flow Statement


Gross margin is 100.00%, with operating and profit margins of -40,795.60% and -40,382.00%.

Gross Margin 100.00%
Operating Margin -40,795.60%
Pretax Margin n/a
Profit Margin -40,382.00%
EBITDA Margin -39,848.00%
EBIT Margin -40,381.60%
FCF Margin -29,115.60%

Dividends & Yields

BioAtla does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Earnings Yield -75.37%
FCF Yield -54.34%
Dividend Growth (YoY) n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Dividend Details

Analyst Forecast

The average price target for BioAtla is $31.62, which is 783.24% higher than the current price. The consensus rating is "Buy".

Price Target $31.62
Price Target Difference 783.24%
Analyst Consensus Buy
Analyst Count 12
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a